CVKD

+ Watchlist + Portfolio

Cadrenal Therapeutics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.97
52-Week Range: $0.85 – $14.50
Market Cap: $2.91M
P/E (TTM): —
EPS (TTM): -4.91
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.71
PEG Ratio: —
Return on Equity: -275.16%
Return on Assets: -125.93%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 3.73
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-8.54M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $966.12K

CVKD Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00
Research & Development	$4.08M	$4.21M	$4.10M
Selling, General & Admin	$3.55M	$6.75M	$9.35M
Operating Expenses	$7.63M	$10.96M	$13.46M
Operating Income	-$7.63M	-$10.96M	-$13.46M
EBITDA	-$8.34M	-$10.96M	-$13.45M
Pretax Income	-$8.36M	-$10.65M	-$13.24M
Net Income	-$8.36M	-$10.65M	-$13.24M
Diluted EPS	-9.29	-8.73	-6.64
Diluted Shares	899465	1.22M	1.99M

CVKD Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$3.53M	-$7.36M	-$12.60M
Capital Expenditure	-$3.25K	-$6.54K	-$5.10K
Free Cash Flow	-$3.53M	-$7.36M	-$12.61M
Depreciation & Amortisation	$1.98K	$1.88K	$6.87K
Stock-Based Compensation	$710.38K	$1.42M	$1.94M
Investing Cash Flow	-$3.25K	-$6.54K	-$5.10K
Financing Cash Flow	$11.90M	$8.98M	$6.60M
Share Repurchases	—	$0.00	-$291.88K
Net Change in Cash	$8.37M	$1.62M	-$6.01M

CVKD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.67M	$1.08M	$688.47K	$666.32K	$771.51K	$705.15K
Selling, General & Admin	$2.25M	$2.66M	$2.04M	$2.40M	$1.74M	$2.63M
Operating Expenses	$3.93M	$3.73M	$2.73M	$3.07M	$2.51M	$3.34M
Operating Income	-$3.93M	-$3.73M	-$2.73M	-$3.07M	-$2.51M	-$3.34M
EBITDA	-$3.92M	-$3.73M	-$2.73M	-$3.06M	-$2.51M	-$3.34M
Pretax Income	-$3.85M	-$3.67M	-$2.69M	-$3.04M	-$2.50M	-$3.32M
Net Income	-$3.85M	-$3.67M	-$2.69M	-$3.04M	-$2.50M	-$3.32M
Diluted EPS	-2.09	-1.87	-1.31	—	-1.04	-1.14
Diluted Shares	1.84M	1.96M	2.04M	—	2.41M	2.91M

CVKD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$7.34M	$5.57M	$3.86M	$4.01M	$2.31M	$2.39M
Receivables	$24.66K	$19.04K	$12.79K	$5.10K	$5.47K	$2.69M
Current Assets	$7.94M	$5.97M	$4.08M	$4.32M	$2.86M	$5.58M
Total Assets	$7.95M	$5.98M	$4.09M	$4.33M	$2.86M	$5.59M
Current Liabilities	$1.84M	$1.68M	$1.35M	$1.59M	$1.06M	$1.50M
Total Liabilities	$1.84M	$1.68M	$1.35M	$1.59M	$1.06M	$1.50M
Retained Earnings	-$29.57M	-$33.24M	-$35.92M	-$38.96M	-$41.46M	-$44.78M
Shareholders' Equity	$6.11M	$4.30M	$2.73M	$2.74M	$1.80M	$4.09M
Working Capital	$6.10M	$4.29M	$2.73M	$2.73M	$1.79M	$4.09M

CVKD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$4.65M	-$3.03M	-$2.36M	-$2.57M	-$3.00M	-$2.23M
Capital Expenditure	-$3.25K	—	-$1.85K	—	—	—
Free Cash Flow	-$4.65M	-$3.03M	-$2.36M	-$2.57M	-$3.00M	-$2.23M
Depreciation & Amortisation	$5.52K	$401.00	$401.00	$555.00	$555.00	$504.00
Stock-Based Compensation	$548.76K	$592.64K	$473.38K	$325.10K	$252.36K	$672.10K
Investing Cash Flow	-$3.25K	$0.00	-$1.85K	$0.00	$0.00	$1.44K
Financing Cash Flow	$1.97M	$1.26M	$648.36K	$2.72M	$1.30M	$2.31M
Net Change in Cash	-$2.68M	-$1.77M	-$1.71M	$147.71K	-$1.70M	$80.00K

Market Snapshot

About

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for kidney disease and related conditions. The company's research programs target treatments for acute kidney injury, chronic kidney disease, and complications arising from renal dysfunction. Cadrenal Therapeutics pursues novel drug candidates designed to protect kidney function and improve outcomes for patients with renal disorders. The company operates in the nephrology pharmaceutical sector, addressing a significant unmet medical need given the prevalence of kidney disease worldwide.